A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.
Hematologic Malignancy|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes
DRUG: CPX-351|DRUG: CPX-351
Pharmacokinetics (PK) of CPX-351, The key PK parameter AUCtau will be assessed, Blood samples will be collected during first induction on Day 1 predose, Day 5 predose, 45 and 90 minutes post infusion start, 2, 3, 4, 6, 8, 24, 48, 96, 168, and 216 hours post Day 5 infusion start.
PK parameter of the individual components of CPX-351, and their respective metabolites, The key PK parameter AUCtau will be assessed, Blood samples will be collected during first induction on Day 1 predose, Day 5 predose, 45 and 90 minutes post infusion start, 2, 3, 4, 6, 8, 24, 48, 96, 168, and 216 hours post Day 5 infusion start.|Incidence of Treatment Emergent Adverse Events (TEAEs), TEAEs are defined as any AE starting after the initiation of the first infusion., Up to 31 months.
This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.